Halozyme Therapeutics (HALO) Tops Q4 EPS by 18c; Guides FY23
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St set for higher open as Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $128.62 --0%
Revenue Growth %: +37.6%
Financial Fact:
Selling, general and administrative: 11.6M
Today's EPS Names:
ATS, SICP, FTCO, More
Revenue Growth %: +37.6%
Financial Fact:
Selling, general and administrative: 11.6M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q4 EPS of $0.48, $0.18 better than the analyst estimate of $0.30. Revenue for the quarter came in at $181 million versus the consensus estimate of $192.05 million.
GUIDANCE:
Halozyme Therapeutics sees FY2023 revenue of $815-845 million, versus the consensus of $868.12 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
- Studio City International Holdings Limited (MSC) Reports Q3 Loss of $0.02
- Scotts Miracle-Gro (SMG) Tops Q4 EPS by 5c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
